The DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Anti‐tumour strategies aiming to target tumour‐associated macrophages
Open accessAbstract
Summary: Tumour‐associated macrophages (TAM s) represent a predominant population of inflammatory cells that present in solid tumours. TAM s are mostly characterized as alternatively activated M2‐like macrophages and are known to orchestrate nearly all stages of tumour progression. Experimental investigations indicate that TAM s contribute to drug‐resistance and radio‐protective effects, and clinical evidence shows that an elevated number of TAM s and their M2 profile are correlated with therapy failure and poor prognosis in cancer patients. Recently, many studies on TAM‐targeted strategies have made significant progress and some pilot works have achieved encouraging results. Among these, connections between some anti‐tumour drugs and their influence on TAM s have been suggested. In this review, we will summarize recent advances in TAM‐targeted strategies for tumour therapy. Based on the proposed mechanisms, those strategies are grouped into four categories: (i) inhibiting macrophage recruitment; (ii) suppressing TAM survival; (iii) enhancing M1‐like tumoricidal activity of TAM s; (iv) blocking M2‐like tumour‐promoting activity of TAM s. It is desired that further attention be drawn to this research field and more effort be made to promote TAM‐targeted tumour therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chatterjee, S., Mookerjee, A., Basu, J. M., Chakraborty, P., Ganguly, A., Adhikary, A., Mukhopadhyay, D., Ganguli, S., Banerjee, R., Ashraf, M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007048 · Cited by 46
RetractedA Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Macrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B.-Z., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,188
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Cited by
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Chanmee, T., Ontong, P., Konno, K., & Itano, N. (2014) · Cancers · doi:10.3390/cancers6031670 · Cited by 1,538
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 737
Tan, H.-Y., Wang, N., Li, S., Hong, M., Wang, X., & Feng, Y. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2795090 · Cited by 657
“Depending on the tumor environment, phenotype of tumor-associated macrophages would be reprogrammed to M1-like phenotype, which is characterized by the antigen presenting property and tumoricidal function that favours tumor regression [38].”
BackgroundAnatomy of a Discovery: M1 and M2 Macrophages
Mills, C. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00212 · Cited by 449
Yang, H., Zhang, Q., Xu, M., Wang, L., Chen, X., Feng, Y., Li, Y., Zhang, X., Cui, W., & Jia, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01165-x · Cited by 440
Targeting folate receptor alpha for cancer treatment
Cheung, A., Bax, H. J., Josephs, D. H., Ilieva, K. M., Pellizzari, G., Opzoomer, J., Bloomfield, J., Fittall, M., Grigoriadis, A., Figini, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9651 · Cited by 430
RETRACTED ARTICLE: LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis
Liang, Y., Song, X., Li, Y., Chen, B., Zhao, W., Wang, L., Zhang, H., Liu, Y., Han, D., Zhang, N., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01206-5 · Cited by 373
Self-citationRetractedStrategies Targeting cAMP Signaling in the Treatment of Polycystic Kidney Disease
Torres, V. E., & Harris, P. C. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040398 · Cited by 289
Chen, X., Zhou, J., Li, X., Wang, X., Lin, Y., & Wang, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.001 · Cited by 287
Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer
Tang, X. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.024 · Cited by 276
“Either manipulation of TAM infiltration and survival or targeting the signal pathways influencing TAMs phenotypes is evidenced to improve outcomes in breast cancers [22].”
BackgroundSelf-citationRIPK3 Orchestrates Fatty Acid Metabolism in Tumor-Associated Macrophages and Hepatocarcinogenesis
Wu, L., Zhang, X., Zheng, L., Zhao, H., Yan, G., Zhang, Q., Zhou, Y., Lei, J., Zhang, J., Wang, J., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0261 · Cited by 272
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Tariq, M., Zhang, J., Liang, G., Ding, L., He, Q., & Yang, B. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25895 · Cited by 178
Liu, L., Yi, H., He, H., Pan, H., Cai, L., & Ma, Y. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.04.043 · Cited by 124
Cornelissen, R., Lievense, L. A., Maat, A. P., Hendriks, R. W., Hoogsteden, H. C., Bogers, A. J., Hegmans, J. P., & Aerts, J. G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106742 · Cited by 91
Chéné, A.-L., d’Almeida, S., Blondy, T., Tabiasco, J., Deshayes, S., Fonteneau, J.-F., Cellerin, L., Delneste, Y., Grégoire, M., & Blanquart, C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.022 · Cited by 84
The Macrophage Response Is Driven by Mesenchymal Stem Cell-Mediated Metabolic Reprogramming
Luque-Campos, N., Bustamante-Barrientos, F. A., Pradenas, C., García, C., Araya, M. J., Bohaud, C., Contreras-López, R., Elizondo-Vega, R., Djouad, F., Luz-Crawford, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624746 · Cited by 82
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Richter, S., Qin, N., Pacak, K., & Eisenhofer, G. (2013) · Advances in Pharmacology · doi:10.1016/b978-0-12-411512-5.00014-2 · Cited by 42
“High HIF2α levels are found in tumour-associated macrophages (TAMs) (Talks et al., 2000), and their number has been associated with poor clinical outcome in different cancers (Tang et al., 2013).”
BackgroundLindskog, E. B., Derwinger, K., Gustavsson, B., Falk, P., & Wettergren, Y. (2014) · BMC Clinical Pathology · doi:10.1186/1472-6890-14-25 · Cited by 22
Metadata
- Authors
- Tang, X., Mo, C., Wang, Y., Wei, D., & Xiao, H.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2013-01-16
- Volume
- 138
- Issue
- 2
- Pages
- 93-104
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W2019179700
- Cited by
- 278
- References
- 154
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.